granted in favour
of the plaintiffs restraining the defendants from manufacturing
LINAGLIPTIN tablets and the said interim order has continued till date.
3. Summons ... parties, Defendants shall not
manufacture, sell, offer for sale and/or use
LINAGLIPTIN or LINAGLIPTIN tablets, or any
other pharmaceutical preparations or formulations
containing LINAGLIPTIN
granted in favour
of the plaintiffs restraining the defendants from manufacturing
LINAGLIPTIN tablets and the said interim order has continued till date.
3. Summons ... parties, Defendants shall not
manufacture, sell, offer for sale and/or use
LINAGLIPTIN or LINAGLIPTIN tablets, or any
other pharmaceutical preparations or formulations
containing LINAGLIPTIN
granted in favour
of the plaintiffs restraining the defendants from manufacturing
LINAGLIPTIN tablets and the said interim order has continued till date.
3. Summons ... parties, Defendants shall not
manufacture, sell, offer for sale and/or use
LINAGLIPTIN or LINAGLIPTIN tablets, or any
other pharmaceutical preparations or formulations
containing LINAGLIPTIN
granted in favour
of the plaintiffs restraining the defendants from manufacturing
LINAGLIPTIN tablets and the said interim order has continued till date.
3. Summons ... parties, Defendants shall not
manufacture, sell, offer for sale and/or use
LINAGLIPTIN or LINAGLIPTIN tablets, or any
other pharmaceutical preparations or formulations
containing LINAGLIPTIN
granted in favour
of the plaintiffs restraining the defendants from manufacturing
LINAGLIPTIN tablets and the said interim order has continued till date.
3. Summons ... parties, Defendants shall not
manufacture, sell, offer for sale and/or use
LINAGLIPTIN or LINAGLIPTIN tablets, or any
other pharmaceutical preparations or formulations
containing LINAGLIPTIN
granted in favour
of the plaintiffs restraining the defendants from manufacturing
LINAGLIPTIN tablets and the said interim order has continued till date.
3. Summons ... parties, Defendants shall not
manufacture, sell, offer for sale and/or use
LINAGLIPTIN or LINAGLIPTIN tablets, or any
other pharmaceutical preparations or formulations
containing LINAGLIPTIN
respondent no. 2 in respect of a medicinal product called 'LINAGLIPTIN', an
anti-diabetic product (hereinafter 'the subject patent'). The subject ... date for the commercial launch of the petitioner's generic
'LINAGLIPTIN' product, i.e. 22nd February, 2022.
Signature Not Verified
Digitally Signed
date for the commercial launch of the petitioner's generic
'LINAGLIPTIN' product, i.e. 22nd February, 2022.
7. Subsequently, on 19th February
